Samsung Biologics publishes prospectus for PolyPeptide public tender offer

Samsung Biologics rights offering highlights future growth, but stock price drops - The Korea Times

Samsung Biologics will issue new shares worth 3 trillion won ($2.17 billion) to finance its planned acquisition of a Swiss-headquartered contract d...